Mutational analysis of genes coding for cell surface proteins in colorectal cancer cell lines reveal novel altered pathways, druggable mutations and mutated epitopes for targeted therapy

Oncotarget

Volumn 5, Issue 19, 2014, Pages 9199-9213

  Donnard, Elisa ^a,b   Asprino, Paula F ^a   Correa, Bruna R ^a   Bettoni, Fabiana ^a   Koyama, Fernanda C ^a,c   Navarro, Fabio C P ^a,b   Perez, Rodrigo O ^c,d   Mariadason, John ^e   Sieber, Oliver M ^f,g   Strausberg, Robert L ^h   Simpson, Andrew J G ^h   Jardim, Denis L F ^a   Reis, Luiz Fernando L ^a   Parmigiani, Raphael B ^a   Galante, Pedro A F ^a   Camargo, Anamaria A ^a,c  

^a HOSPITAL SÍRIO LIBANÊS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Brazil)

^d Angelita and Joaquim Gama Institute   (Brazil)

^e OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

^f WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

Cell surface proteins; Colorectal cancer; Somatic mutations; Targeted therapy

Indexed keywords

CELL SURFACE PROTEIN; EPHRIN RECEPTOR A2; EPITOPE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 5; MEMBRANE PROTEIN;

AMINO ACID SUBSTITUTION; ARTICLE; AXL GENE; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; EPHA2 GENE; FAM38A GENE; FGFRL1 GENE; GENE; GENE EXPRESSION; IGFLR1 GENE; INDEL MUTATION; MOLECULARLY TARGETED THERAPY; MUTATIONAL ANALYSIS; PKD1 GENE; SEMA4C GENE; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; SLC26A6 GENE; SLC36A1 GENE; SOMATIC MUTATION; TMEM136 GENE; WDR81 GENE; CACO 2 CELL LINE; COLORECTAL TUMOR; DNA MUTATIONAL ANALYSIS; DNA SEQUENCE; DRUG DEVELOPMENT; GENETICS; HCT116 CELL LINE; HT 29 CELL LINE; HUMAN; NUCLEOTIDE SEQUENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR CELL LINE;

BASE SEQUENCE; CACO-2 CELLS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; DRUG DISCOVERY; EPITOPES; HCT116 CELLS; HT29 CELLS; HUMANS; MEMBRANE PROTEINS; MOLECULAR TARGETED THERAPY; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE ANALYSIS, DNA;

EID: 84910029110     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2374     Document Type: Article

References (79)

1. Siegel R, Desantis C and Jemal A. Colorectal cancer statistics, 2014. CA. Cancer J. Clin. 2014; 64:104-17.
2. Arnold D and Seufferlein T. Targeted treatments in colorectal cancer: state of the art and future perspectives. Gut. 2010; 59:838-58.
3. Fearon ER. Molecular genetics of colorectal cancer. Annu. Rev. Pathol. 2011; 6:479-507.
4. Sjöblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P and Farrell C. et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2006; 314:268-74.
5. TCGA, Cancer T, Atlas G: Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487:330-7.
6. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, Meyerson M, Gabriel SB, LanderES and Getz G. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014; 505:495-501.
7. Harrow J, Frankish A, Gonzalez JM, Tapanari E, DiekhansM, Kokocinski F, Aken BL, Barrell D, ZadissaA, SearleS, Barnes I, Bignell A, Boychenko V and et al. GENCODE: the reference human genome annotation for The ENCODE Project. Genome Res. 2012; 22:1760-74.
8. Rask-Andersen M, Almén MS and Schiöth HB. Trends in the exploitation of novel drug targets. Nat. Rev. Drug Discov. 2011; 10:579-90.
9. Da Cunha JP, Galante PA, de Souza JE, de Souza RF, Carvalho PM, Ohara DT, Moura RP, Oba-Shinja SM, MarieSK, Silva WA Jr, Perez RO, Stransky B, PieprzykM and et al. Bioinformatics construction of the human cell surfaceome. Proc Natl Acad Sci U S A. 2009; 106: 16752-16757.
10. Da Cunha JPC, Galante PAF, de Souza JES, PieprzykM, Carraro DM, Old LJ, Camargo AA and de Souza SJ. Thehuman cell surfaceome of breast tumors. Biomed Res. Int. 2013; 2013:976816.
11. Mouradov D, Sloggett C, Jorissen RN, Love CG, Li S, Burgess AW, Arango D, Strausberg RL, Buchanan D, Wormald S, O'Connor L, Wilding JL, Bicknell D and et al. Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer. Cancer Res. 2014; 74:3238-47.
12. Flannery E and Duman-Scheel M. Semaphorins at the interfacemmof development and cancer. Curr. Drug Targets. 2009; 10:611-9.
13. Gu C and Giraudo E. The role of semaphorins and their receptors in vascular development and cancer. Exp. Cell Res. 2013; 319:1306-16.
14. Wu H, Fan J, Zhu L, Liu S, Wu Y, Zhao T, Wu Y, DingX, Fan W and Fan M. Sema4C expression in neural stem/progenitor cells and in adult neurogenesis induced by cerebral ischemia. J. Mol. Neurosci. 2009; 39:27-39.
15. Zeng R, Han M, Luo Y, Li C, Pei G, Liao W, Bai S, GeS, Liu X and Xu G. Role of Sema4C in TGF-ß1-induced mitogen-activated protein kinase activation and epithelial-mesenchymal transition in renal tubular epithelial cells. Nephrol. Dial. Transplant. 2011; 26:1149-56.
16. Ch'ng ES and Kumanogoh A. Roles of Sema4D and Plexin-B1 in tumor progression. Mol. Cancer. 2010; 9:251.
17. Guo G, Sun X, Chen C, Wu S, Huang P, Li Z, Dean M, Huang Y, Jia W, Zhou Q, Tang A, Yang Z and Li X. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat. Genet. 2013; 45:1459-63.
18. Trueb B. Biology of FGFRL1, the fifth fibroblast growth factor receptor. Cell. Mol. Life Sci. 2011; 68:951-64.
19. Sato T, Oshima T, Yoshihara K, Yamamoto N, YamadaR, Nagano Y, Fujii S, Kunisaki C, Shiozawa M, Akaike M, Rino Y, Tanaka K and Masuda M. Overexpression of the fibroblast growth factor receptor-1 gene correlates with liver metastasis in colorectal cancer. Oncol. Rep. 2009; 21:211-216.
20. Griffith M, Griffith OL, Coffman AC, Weible J V, McMichael JF, Spies NC, Koval J, Das I, Callaway MB, Eldred JM, Miller CA, Subramanian J, Govindan R and etal. DGIdb: mining the druggable genome. Nat. Methods. 2013; 10:1209-10.
21. El-Gebali S, Bentz S, Hediger M A, Anderle P and et al. Solute carriers (SLCs) in cancer. Mol. Aspects Med. 2013; 34:719-34.
22. Kunická T SP. Importance of ABCC1 for cancer therapy and prognosis. Drug Metab. Rev. 2014.
23. Paccez JD, Vogelsang M, Parker MI and Zerbini LF. The receptor tyrosine kinase Axl in cancer: biological functions and therapeutic implications. Int. J. Cancer. 2014; 134:1024-33.
24. Craven RJ and Xu L. Receptor tyrosine kinases expressed in metastatic colon cancer. Int. J. Cancer. 1995; 60:791-797.
25. Dunne PD, McArt DG, Blayney JK, Kalimutho M, GreerS, Wang T, Srivastava S, Ong CW, Arthur K, Loughrey M, Redmond K, Longley DB, Salto-Tellez M and et al. AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer. Clin. Cancer Res. 2014; 20:164-75.
26. Ireton RC and Chen J. EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics. Curr. Cancer Drug Targets. 2005; 5:149-57.
27. Saito T, Masuda N, Miyazaki T, Kanoh K, Suzuki H, Shimura T, Asao T and Kuwano H. Expression of EphA2 and E-cadherin in colorectal cancer: Correlation with cancer metastasis. Oncol. Rep. 2004; 11:605-611.
28. Kataoka H, Igarashi H, Kanamori M, Ihara M, WangJ-D, Wang Y-J, Li Z-Y, Shimamura T, Kobayashi T, MaruyamaK, Nakamura T, Arai H, Kajimura M and et al. Correlation of EPHA2 overexpression with high microvessel count in human primary colorectal cancer. Cancer Sci. 2004; 95:136-41.
29. Bogan C, Chen J, O'Sullivan MG and Cormier RT. Loss of EphA2 receptor tyrosine kinase reduces ApcMin/+ tumorigenesis. Int. J. Cancer. 2009; 124:1366-71.
30. Herath NI, Doecke J, Spanevello MD, Leggett Ba and Boyda W. Epigenetic silencing of EphA1 expression in colorectal cancer is correlated with poor survival. Br. J. Cancer. 2009; 100:1095-102.
31. Dong Y, Wang J, Sheng Z, Li G, Ma H, Wang X, ZhangR, Lu G, Hu Q, Sugimura H and Zhou X. Downregulation of EphA1 in colorectal carcinomas correlates with invasion and metastasis. Mod. Pathol. 2009; 22:151-60.
32. McDermott U, Downing JR and Stratton MR. Genomics and the continuum of cancer care. N. Engl. J. Med. 2011; 364:340-50.
33. Chang K, Creighton CJ, Davis C, Donehower L, DrummondJ, Wheeler D, Ally A, Balasundaram M, BirolI, Butterfield YSN, Chu A, Chuah E, Chun H-JE and et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat. Genet. 2013; 45:1113-20.
34. Hopkins AL and Groom CR. The druggable genome. Nat. Rev. Drug Discov. 2002; 1:727-30.
35. Overington JP, Al-Lazikani B and Hopkins AL. How many drug targets are thereOE. Nat. Rev. Drug Discov. 2006; 5:993-6.
36. Olaya-Abril A, Jiménez-Munguía I, Gómez-Gascón L and Rodríguez-Ortega MJ. Surfomics: shaving live organisms for a fast proteomic identification of surface proteins. J. Proteomics. 2014; 97:164-76.
37. Rehman M and Tamagnone L. Semaphorins in cancer: biological mechanisms and therapeutic approaches. Semin. Cell Dev. Biol. 2013; 24:179-89.
38. Conrotto P, Valdembri D, Corso S, Serini G, TamagnoneL, Comoglio PM, Bussolino F and Giordano S. Sema4D induces angiogenesis through Met recruitment by Plexin B1. Blood. 2005; 105:4321-9.
39. Basile JR, Castilho RM, Williams VP and Gutkind JS. Semaphorin 4D provides a link between axon guidance processes and tumor-induced angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 2006; 103:9017-22.
40. Dieci MV, Arnedos M, Andre F and Soria JC. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov. 2013; 3:264-79.
41. Khan G, Moss R A, Braiteh F and Saltzman M. Proactive strategies for regorafenib in metastatic colorectal cancer: implications for optimal patient management. Cancer Manag. Res. 2014; 6:93-103.
42. Mahadevan D, Cooke L, Riley C, Swart R, Simons B, Della Croce K, Wisner L, Iorio M, Shakalya K, Garewal H, Nagle R and Bearss D. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene. 2007; 26:3909-19.
43. Gioia R, Leroy C, Drullion C, Lagarde V, Etienne G, Dulucq S, Lippert E, Roche S, Mahon F-X and PasquetJ-M. Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells. Blood. 2011; 118:2211-21.
44. Liu L, Greger J, Shi H, Liu Y, Greshock J, Annan R, HalseyW, Sathe GM, Martin A-M and Gilmer TM. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res. 2009; 69:6871-8.
45. Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, NilssonMB, Gudikote J and Tran H. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin. Cancer Res. 2013; 19:279-90.
46. Heckmann D, Maier P, Laufs S, Li L, Sleeman JP, TrunkMJ, Leupold JH, Wenz F, Zeller WJ, Fruehauf S and Allgayer H. The disparate twins: a comparative study of CXCR4 and CXCR7 in SDF-1α-induced gene expression, invasion and chemosensitivity of colon cancer. Clin. Cancer Res. 2014; 20:604-16.
47. Verma A, Warner SL, Vankayalapati H, Bearss DJ and Sharma S. Targeting Axl and Mer kinases in cancer. Mol. Cancer Ther. 2011; 10:1763-73.
48. Burbridge MF, Bossard CJ, Saunier C, Fejes I, Bruno A, Léonce S, Ferry G, Da Violante G, Bouzom F, CattanV, Jacquet-Bescond A, Comoglio PM and Lockhart BP. S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab. Mol. Cancer Ther. 2013; 12:1749-62.
49. Bardelli A, Parsons DW, Silliman N, Ptak J, Szabo S, SahaS, Markowitz S, Willson JK V, Parmigiani G, KinzlerKW, Vogelstein B, Velculescu VE and et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science. 2003; 300:949.
50. Boyd AW, Bartlett PF and Lackmann M. Therapeutic targeting of EPH receptors and their ligands. Nat. Rev. Drug Discov. 2014; 13:39-62.
51. Montero JC, Seoane S, Ocaña A and Pandiella A. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin. Cancer Res. 2011; 17:5546-52.
52. Brantley DM, Cheng N, Thompson EJ, Lin Q, Brekken RA, Thorpe PE, Muraoka RS, Cerretti DP, Pozzi A, Jackson D, Lin C and Chen J. Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene. 2002; 21:7011-26.
53. Dobrzanski P, Hunter K, Jones-Bolin S, Chang H, RobinsonC, Pritchard S, Zhao H and Ruggeri B. Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist. Cancer Res. 2004; 64:910-919.
54. Carles-Kinch K, Kilpatrick KE, Stewart JC and Kinch MS. Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. Cancer Res. 2002; 62:2840-2847.
55. Heemskerk B, Kvistborg P and Schumacher TNM. The cancer antigenome. EMBO J. 2013; 32:194-203.
56. Gjertsen MK, Buanes T, Rosselanda R, Bakka A, Gladhaug I, Søreide O, Eriksen J A, Møller M, BaksaasI, Lothe Ra, Saeterdal I and Gaudernack G. Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma. Int. J. Cancer. 2001; 92:441-50.
57. Overwijk WW, Wang E, Marincola FM, Rammensee H-G and Restifo NP. Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumors. J. Immunother. cancer. 2013; 1:11.
58. Brown SD, Warren RL, Gibb EA, Martin SD, Spinelli JJ, Nelson BH and Holt RA. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res. 2014; 24:743-750.
59. Lawrence MS, Stojanov P, Polak P, Kryukov G V, CibulskisK, Sivachenko A, Carter SL, Stewart C, MermelCH, Roberts S A, Kiezun A, Hammerman PS, McKenna A and et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013; 499:214-8.
60. Brahmer JR. Immune checkpoint blockade: the hope for immunotherapy as a treatment of lung cancer? Semin. Oncol. 2014; 41:126-32.
61. Naidoo J, Page DB and Wolchok JD. Immune Checkpoint Blockade. Hematol. Oncol. Clin. North Am. 2014; 28: 585-600.
62. Dolcetti R, Viel A, Doglioni C, Russo A, Guidoboni M, Capozzi E, Vecchiato N, Macrì E, Fornasarig M and Boiocchi M. High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am. J. Pathol. 1999; 154:1805-13.
63. Lipson EJ. Re-orienting the immune system: Durable tumor regression and successful re-induction therapy using anti-PD1 antibodies. Oncoimmunology. 2013; 2:e23661.
64. Dienstmann R, Serpico D, Rodon J, Saura C, MacarullaT, Elez E, Alsina M, Capdevila J, Perez-Garcia J, Sánchez-OlléG, Aura C, Prudkin L, Landolfi S and et al. Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials. Mol. Cancer Ther. 2012; 11:2062-71.
65. Manning G, Whyte DB, Martinez R, Hunter T and Sudarsanam S. The protein kinase complement of the human genome. Science. 2002; 298:1912-1934.
66. Li H and Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009; 25:1754-1760.
67. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, HomerN, Marth G, Abecasis G and Durbin R. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009; 25:2078-2079.
68. Kumar P, Henikoff S and Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat. Protoc. 2009; 4:1073-1081.
69. Adzhubei I, Jordan DM and Sunyaev SR. Predicting functional effect of human missense mutations using PolyPhen-2. Curr. Protoc. Hum. Genet. 2013; Chapter 7: Unit7.20.
70. Reva B, Antipin Y and Sander C. Predicting the functionalimpact of protein mutations: application to cancer genomics. Nucleic Acids Res. 2011; 39:e118.
71. Trapnell C, Pachter L and Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics. 2009; 25:1105-11.
72. Trapnell C, Williams BA, Pertea G, Mortazavi A, KwanG, van Baren MJ, Salzberg SL, Wold BJ and Pachter L. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat. Biotechnol. 2010; 28:511-5.
73. Mortazavi A, Williams BA, McCue K, Schaeffer L and Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat. Methods. 2008; 5:621-8.
74. Marinov GK, Williams BA, McCue K, Schroth GP, GertzJ, Myers RM and Wold BJ. From single-cell to cell-pool transcriptomes: stochasticity in gene expression and RNA splicing. Genome Res. 2014; 24:496-510.
75. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov G V, Sonkin D, Reddy A, Liu M, Murray L and et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483:603-7.
76. Segal NH, Parsons DW, Peggs KS, Velculescu V, KinzlerKW, Vogelstein B and Allison JP. Epitope landscape in breast and colorectal cancer. Cancer Res. 2008; 68:889-92.
77. Reche PA and Reinherz EL. Prediction of peptide-MHC binding using profiles. Methods Mol. Biol. 2007; 409: 185-200.
78. Lundegaard C, Lamberth K, Harndahl M, Buus S, LundO and Nielsen M. NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class Iaffinities for peptides of length 8-11. Nucleic Acids Res. 2008; 36: W509-12.
79. Nielsen M, Lundegaard C, Lund O and Kesmir C. The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage. Immunogenetics. 2005; 57:33-41.